• Recruiting

NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM

Updated: Jun 8

FUMANBA-1

NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)


CT103A

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)


This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM.


Sponsor

Nanjing IASO Biotherapeutics Co.,Ltd


Locations:

China

 

ClinicalTrials.gov Identifier: NCT05066646


Official Title: Phase 1/2 Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma


First Posted: October 4, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: CT103A

 

CT-103A


Autologous Anti-BCMA CAR T Cells CT103A (Code C185123)

Autologous Anti-BCMA CAR T Cells CT103A

Autologous Anti-BCMA CAR-T Cells CT103A

Autologous Anti-BCMA CAR-transduced T-cells CT103A

CT 103A

CT-103A

CT103A

 

EHA 2022 Oral Presentation

EHA 2022 - HYBRID - JUNE 9-17 - VIENNA

UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A, FULLY HUMAN BCMA-DIRECTED CAR T CELLS, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA


Click here to see Abstract details

 

Locations

China

China, Anhui

China, Henan

China, Hubei

China, Hunan

China, Jiangsu

China, Zhejiang



Posts Archive